Use of antipsychotics in children and adolescents.

The comparable efficacy and improved safety of the atypical antipsychotics compared with the traditional antipsychotic agents in the treatment of schizophrenia and other disorders in adults have prompted the use of these agents in children and adolescents. The atypical antipsychotics are increasingly being used in children and adolescents with a variety of different psychiatric diagnoses, including schizophrenia, bipolar disorder, autism/pervasive developmental disorders, conduct disorder, depression, anxiety disorders, tic disorders, delirium, and eating disorders. Unfortunately, clinical use of these agents in pediatric patients has far exceeded the limited evidence from randomized controlled trials. This article reviews the available evidence from the published literature on the use of the atypical antipsychotics in children and adolescents with schizophrenia, bipolar disorder, and maladaptive aggression associated with autism/pervasive developmental disorders and conduct disorder/disruptive behavior disorders.

[1]  M. State,et al.  Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[2]  R. Findling,et al.  Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[3]  I. Smith,et al.  Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders , 2004, Pediatrics.

[4]  F. Rachid,et al.  Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. , 2004, The Journal of clinical psychiatry.

[5]  C. McDougle,et al.  A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. , 2004, The Journal of clinical psychiatry.

[6]  C. McDougle,et al.  Aripiprazole for maladaptive behavior in pervasive developmental disorders. , 2004, Journal of child and adolescent psychopharmacology.

[7]  R. Findling,et al.  Quetiapine in nine youths with autistic disorder. , 2004, Journal of child and adolescent psychopharmacology.

[8]  D. Safer.  A Comparison of Risperidone-Induced Weight Gain Across the Age Span , 2004, Journal of clinical psychopharmacology.

[9]  J. Rapoport,et al.  Looking for childhood schizophrenia: case series of false positives. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[10]  E. Spina,et al.  Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. , 2004, Journal of child and adolescent psychopharmacology.

[11]  R. Kauffman,et al.  Pharmacokinetic effects of aripiprazole in children and adolescents with conduct disorder , 2004 .

[12]  P. Keck,et al.  Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. , 2004, The American journal of psychiatry.

[13]  V. Kusumakar,et al.  Growth and sexual maturation during long-term treatment with risperidone. , 2004, The American journal of psychiatry.

[14]  R. Findling,et al.  Atypical antipsychotics in the treatment of children and adolescents: clinical applications. , 2004, The Journal of clinical psychiatry.

[15]  R. Findling,et al.  Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. , 2004, The American journal of psychiatry.

[16]  S. Minsky,et al.  Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. , 2004, The Journal of clinical psychiatry.

[17]  N. M. Mukaddes,et al.  Short-Term Efficacy and Safety of Risperidone in Young Children with Autistic Disorder (AD) , 2004, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[18]  C. Perry,et al.  Aripiprazole: in acute mania associated with bipolar I disorder. , 2004, CNS drugs.

[19]  M. Tohen,et al.  Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. , 2004, The American journal of psychiatry.

[20]  J. Lieberman,et al.  A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial , 2004, Neuropsychopharmacology.

[21]  C. Stavrakaki,et al.  Olanzapine in the treatment of pervasive developmental disorders: a case series analysis. , 2004, Journal of psychiatry & neuroscience : JPN.

[22]  L. Balant,et al.  Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia , 2004, European archives of psychiatry and neurological sciences.

[23]  M. Crismon,et al.  Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[24]  C. Nemeroff,et al.  Depression and bipolar support alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in children and adolescents. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[25]  J. Kane.  Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. , 2003, The Journal of clinical psychiatry.

[26]  C. McDougle,et al.  Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[27]  R. Emsley,et al.  A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. , 2003, Archives of general psychiatry.

[28]  H. Steiner,et al.  Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. , 2003, The Journal of clinical psychiatry.

[29]  E. Heyneman.  The aggressive child. , 2003, Child and adolescent psychiatric clinics of North America.

[30]  M. Larson,et al.  Possible ziprasidone-induced mania. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[31]  P. Brovedani,et al.  A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. , 2003, The Journal of clinical psychiatry.

[32]  P. Keck,et al.  A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. , 2003, The American journal of psychiatry.

[33]  S. Minsky,et al.  A program for managing weight gain associated with atypical antipsychotics. , 2003, Psychiatric services.

[34]  Abraham Weizman,et al.  Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. , 2003, The Journal of clinical psychiatry.

[35]  S. Potkin,et al.  Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. , 2003, Archives of general psychiatry.

[36]  M. Fristad,et al.  Family psychoeducation: an adjunctive intervention for children with bipolar disorder. , 2003, Biological psychiatry.

[37]  R. Mailman,et al.  Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.

[38]  R. Weizman,et al.  Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia , 2003, Journal of Neural Transmission.

[39]  K. Chang,et al.  Psychopharmacologic Strategies for the Treatment of Aggression in Juveniles , 2003, CNS Spectrums.

[40]  S. Potkin,et al.  Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. , 2003, The American journal of psychiatry.

[41]  R. Balon.  Child and Adolescent Psychopharmacology , 2003 .

[42]  A. Wieck,et al.  Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences , 2003, British Journal of Psychiatry.

[43]  E. Youngstrom,et al.  A prospective, open-label trial of olanzapine in adolescents with schizophrenia. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[44]  J. Rapoport,et al.  Clozapine Pharmacokinetics in Children and Adolescents with Childhood-Onset Schizophrenia , 2003, Journal of clinical psychopharmacology.

[45]  David Taylor.  Ziprasidone in the Management of Schizophrenia , 2003, CNS drugs.

[46]  M. Crismon,et al.  Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[47]  Abraham Weizman,et al.  Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. , 2003, Journal of child and adolescent psychopharmacology.

[48]  M. Sorter,et al.  Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. , 2003, Journal of child and adolescent psychopharmacology.

[49]  G. Farley,et al.  A 1-year open-label trial of olanzapine in school-age children with schizophrenia. , 2003, Journal of child and adolescent psychopharmacology.

[50]  H. van Engeland,et al.  Open-Label Study of Olanzapine in Children with Pervasive Developmental Disorder , 2002, Journal of clinical psychopharmacology.

[51]  S. Strakowski,et al.  A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[52]  J. Kane,et al.  Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. , 2002, The Journal of clinical psychiatry.

[53]  M. Aman,et al.  Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[54]  C. Binder,et al.  Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. , 2002, Pediatrics.

[55]  C. McDougle,et al.  Case series: use of ziprasidone for maladaptive symptoms in youths with autism. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[56]  C. McDougle,et al.  Risperidone in children with autism and serious behavioral problems. , 2002, The New England journal of medicine.

[57]  R. Findling,et al.  Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. , 2002, The American journal of psychiatry.

[58]  G. Sachs,et al.  Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. , 2002, The American journal of psychiatry.

[59]  Kevin D Burris,et al.  Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors , 2002, Journal of Pharmacology and Experimental Therapeutics.

[60]  N. Patel,et al.  Experience with ziprasidone. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[61]  G. Maguire.  Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. , 2002, The Journal of clinical psychiatry.

[62]  R. Conley,et al.  Current status of antipsychotic treatment. , 2002, Current drug targets. CNS and neurological disorders.

[63]  G. Maislin,et al.  Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[64]  G. Masi,et al.  Clozapine in adolescent inpatients with acute mania. , 2002, Journal of child and adolescent psychopharmacology.

[65]  R. Schweitzer,et al.  "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. , 2002, Schizophrenia bulletin.

[66]  M. DelBello,et al.  DSM-IV mania symptoms in a prepubertal and early adolescent bipolar disorder phenotype compared to attention-deficit hyperactive and normal controls. , 2002, Journal of child and adolescent psychopharmacology.

[67]  J. Lieberman,et al.  The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches , 2001, Biological Psychiatry.

[68]  J. Lewis,et al.  A study of quetiapine: efficacy and tolerability in psychotic adolescents. , 2001, Journal of child and adolescent psychopharmacology.

[69]  Shitij Kapur,et al.  Dopamine D2 Receptor Occupancy Is a Common Mechanism Underlying Animal Models of Antipsychotics and Their Clinical Effects , 2001, Neuropsychopharmacology.

[70]  J. Hebebrand,et al.  Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. , 2001, Journal of psychiatric research.

[71]  P. Brovedani,et al.  Open trial of risperidone in 24 young children with pervasive developmental disorders. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[72]  R. Malone,et al.  Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[73]  J. Buitelaar,et al.  A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. , 2001, The Journal of clinical psychiatry.

[74]  M. Tohen,et al.  Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. , 2001, The Journal of clinical psychiatry.

[75]  M. van Bellinghen,et al.  Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. , 2001, Journal of child and adolescent psychopharmacology.

[76]  L. Catapano-Friedman.  Effectiveness of quetiapine in the management of psychotic depression in an adolescent boy with bipolar disorder, mixed, with psychosis. , 2001, Journal of child and adolescent psychopharmacology.

[77]  M. Tohen,et al.  A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. , 2001, Journal of child and adolescent psychopharmacology.

[78]  J. Aubry,et al.  Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. , 2000, The Journal of clinical psychiatry.

[79]  M. Tohen,et al.  Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. , 2000, Archives of general psychiatry.

[80]  R. Findling,et al.  Paediatric uses of atypical antipsychotics , 2000, Expert opinion on pharmacotherapy.

[81]  R. Malone,et al.  A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. , 2000, Archives of general psychiatry.

[82]  M. Schluchter,et al.  A double-blind pilot study of risperidone in the treatment of conduct disorder. , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.

[83]  J. Rapoport,et al.  Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. , 2000, Journal of clinical psychopharmacology.

[84]  L. Wilkinson,et al.  Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. , 2000, The Journal of clinical psychiatry.

[85]  R. Barkley,et al.  A Pilot Study of Methyiphenidate, Clonidine, or the Combination in ADHD Comorbid with Aggressive Oppositional Defiant or Conduct Disorder , 2000, Clinical pediatrics.

[86]  J. Buitelaar.  Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. , 2000, Journal of child and adolescent psychopharmacology.

[87]  D. Cicchetti,et al.  Risperidone-associated weight gain in children and adolescents: a retrospective chart review. , 2000, Journal of child and adolescent psychopharmacology.

[88]  P. Muglia,et al.  Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. , 2000, Journal of child and adolescent psychopharmacology.

[89]  M. Berk,et al.  Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. , 1999, International clinical psychopharmacology.

[90]  J. Biederman,et al.  Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[91]  P. Keck,et al.  Olanzapine in the treatment of adolescent acute mania: a report of seven cases. , 1999, Journal of affective disorders.

[92]  J. Elia,et al.  Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders. , 1999, The Journal of clinical psychiatry.

[93]  D. Behar,et al.  Quetiapine for refractory mania in a child. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[94]  C. McDougle,et al.  Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. , 1999, Journal of clinical psychopharmacology.

[95]  R. Malone,et al.  Novel antipsychotic medications in the treatment of children and adolescents. , 1999, Psychiatric services.

[96]  J. Rapoport,et al.  Elevated prolactin in pediatric patients on typical and atypical antipsychotics. , 1999, Journal of child and adolescent psychopharmacology.

[97]  J. Bregman,et al.  Open-label quetiapine in the treatment of children and adolescents with autistic disorder. , 1999, Journal of child and adolescent psychopharmacology.

[98]  F. Goodwin,et al.  Use of atypical antipsychotic agents in bipolar and schizoaffective disorders: review of the empirical literature. , 1999, Journal of clinical psychopharmacology.

[99]  Abraham Weizman,et al.  Use of atypical neuroleptics in child and adolescent psychiatry. , 1998, The Journal of clinical psychiatry.

[100]  M. Tohen,et al.  Olanzapine versus placebo in the treatment of acute mania , 1998, European Psychiatry.

[101]  R. Lewis.  Typical and Atypical Antipsychotics in Adolescent Schizophrenia: Efficacy, Tolerability, and Differential Sensitivity to Extrapyramidal Symptoms , 1998, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[102]  J. Lindenmayer,et al.  Olanzapine-induced manic-like syndrome. , 1998, The Journal of clinical psychiatry.

[103]  R. Nicolson,et al.  An open trial of risperidone in young autistic children. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[104]  H. Lane,et al.  Mania induced by risperidone: dose related? , 1998, The Journal of clinical psychiatry.

[105]  J. A. London.  Mania associated with olanzapine. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[106]  T. Cooper,et al.  Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[107]  J. Rapoport,et al.  Childhood-onset schizophrenia: An open-label study of olanzapine in adolescents , 1998, Schizophrenia Research.

[108]  H. Abikoff,et al.  Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. , 1997, Archives of general psychiatry.

[109]  Abraham Weizman,et al.  An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia , 1997, British Journal of Psychiatry.

[110]  C. McDougle,et al.  Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[111]  J. Gorman,et al.  Risperidone in adolescents with schizophrenia: an open pilot study. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[112]  D. Connor,et al.  Combined pharmacotherapy in children and adolescents in a residential treatment center. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[113]  C. Pataki,et al.  Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. , 1997, Journal of child and adolescent psychopharmacology.

[114]  M. Wiznitzer,et al.  An open clinical trial of risperidone monotherapy in young children with autistic disorder. , 1997, Psychopharmacology bulletin.

[115]  H. Meltzer,et al.  Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. , 1997, The American journal of psychiatry.

[116]  C. Eggers,et al.  The long-term course of childhood-onset schizophrenia: a 42-year followup. , 1997, Schizophrenia bulletin.

[117]  J. Rapoport,et al.  Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison , 1996 .

[118]  J. Overall,et al.  Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[119]  S. Fisman,et al.  Use of risperidone in pervasive developmental disorders: a case series. , 1996, Journal of child and adolescent psychopharmacology.

[120]  D. Graeber,et al.  Manic symptoms associated with initiation of risperidone. , 1996, The American journal of psychiatry.

[121]  J. Kenny,et al.  Adolescent schizophrenia: A methodologic review of the current neuroimaging and neuropsychologic literature , 1995, Journal of autism and developmental disorders.

[122]  J. Overall,et al.  Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.

[123]  B. Grannemann,et al.  Clozapine Treatment of Children and Adolescents with Bipolar Disorder and Schizophrenia: A Clinical Case Series , 1995 .

[124]  V. Kafantaris,et al.  An update on the use of lithium carbonate in aggressive children and adolescents with conduct disorder. , 1995, Psychopharmacology bulletin.

[125]  M. Keshavan,et al.  Predictors of acute dystonia in first-episode psychotic patients. , 1994, The American journal of psychiatry.

[126]  D. Fuchs.  Clozapine treatment of bipolar disorder in a young adolescent. , 1994, Journal of the American Academy of Child and Adolescent Psychiatry.

[127]  J. Rapoport,et al.  An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. , 1994, Journal of the American Academy of Child and Adolescent Psychiatry.

[128]  J. Zito.  Pharmacoepidemiology of 330 Child/Adolescent Psychiatric Patients , 1994 .

[129]  H. Remschmidt,et al.  An Open Trial of Clozapine in Thirty-Six Adolescents with Schizophrenia , 1994 .

[130]  J. Asarnow,et al.  Childhood-onset schizophrenia: a followup study. , 1994, Schizophrenia bulletin.

[131]  H. Remschmidt,et al.  Childhood-onset schizophrenia: history of the concept and recent studies. , 1994, Schizophrenia bulletin.

[132]  M. Campbell,et al.  Children with schizophrenia: diagnosis, phenomenology, and pharmacotherapy. , 1994, Schizophrenia bulletin.

[133]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[134]  R. Perry,et al.  The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children , 1989, Journal of autism and developmental disorders.

[135]  J. Overall,et al.  Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. , 1989, Journal of the American Academy of Child and Adolescent Psychiatry.

[136]  Philip Seeman,et al.  Human brain dopamine receptors in children and aging adults , 1987, Synapse.

[137]  R. Perry,et al.  Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. , 1984, The American journal of psychiatry.

[138]  R. Perry,et al.  Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. , 1984, Archives of general psychiatry.

[139]  W. D. Erickson,et al.  Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. , 1984, The American journal of psychiatry.

[140]  G. Keepers,et al.  Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. , 1983, Archives of general psychiatry.

[141]  E. Persad,et al.  A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. , 1980, Journal of affective disorders.

[142]  D. Gallant,et al.  A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. , 1976, Current therapeutic research, clinical and experimental.

[143]  W. Goodson,et al.  Sudden unexplained death in a psychiatric patient taking thioridazine. , 1976, Southern medical journal.

[144]  T. Giles,et al.  Death associated with ventricular arrhythmia and thioridazine hydrochloride. , 1968, JAMA.